Annual Conference

Nominations

No products in the cart.

Annual Conference

Nominations

No products in the cart.

Articles of Interest

Home Archive "Articles of Interest"
Expansion of Buprenorphine Treatment via Telemedicine Encounter
Addiction Medicine Updates Articles of Interest Legislation

Expansion of Buprenorphine Treatment via Telemedicine Encounter

Overview of the Final Rule The DEA and the Department of Health and Human Services (HHS) published a final rule titled “Expansion of Buprenorphine Treatment via Telemedicine Encounter” on January 17, 2025. This rule permits DEA-registered practitioners to prescribe buprenorphine, a Schedule III controlled substance approved by the FDA for treating opioid use disorder (OUD), through...
DEA Rules Extend Controlled Substance Telemedicine
Addiction Medicine Updates Articles of Interest Legislation

New DEA Rule Extends Controlled Substance Telemedicine Prescribing Flexibilities One More Year

The Drug Enforcement Administration (DEA) just released a new regulation temporarily extending the COVID-era flexibilities for prescribing controlled substances via telemedicine. This third extension continues the “full set” of telemedicine prescribing flexibilities, referencing the two DEA letters that authorized telemedicine waivers, with a new expiration date of December 31, 2025....
U.S. Supreme Court Refuses to Hear Tobacco Industry’s Challenge to Graphic Cigarette Warnings
Articles of Interest Legislation

In Victory for Public Health, U.S. Supreme Court Refuses to Hear Tobacco Industry’s Challenge to Graphic Cigarette Warnings

Today’s Supreme Court decision is a giant step toward finally implementing graphic cigarette warnings in the United States. Graphic warnings are a best-practice policy, and they are long-overdue in the United States. These warnings were first required by Congress in 2009 and have been repeatedly delayed by tobacco industry legal challenges. The graphic warnings will show and tell the...
Selective Dopamine D3 Partial Agonist VK4-40 Reduces d-Amphetamine Reinforcement but Not Cocaine in Monkeys
Articles of Interest

Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement

Highlights There are still no FDA-approved pharmacotherapies for stimulant use disorders. One potential pharmacotherapy is (±)VK4–40, a novel dopamine D3 receptor (D3R) partial agonist. In rhesus monkeys, (±)VK4–40 reduced the reinforcing strength of d-amphetamine but not cocaine under a progressive-ratio schedule. When self-administered, peak breakpoints for (±)VK4–40 were...
Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial
Articles of Interest

Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial

Abstract Aims To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers. Methods We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing to transfer to buprenorphine could either choose or be randomized to a low-dose transfer or standard care transfer as per NSW health...
Pending DEA Extension on Prescription of Controlled Substances via Telemedicine
Addiction Medicine Updates Articles of Interest Legislation

Pending DEA Extension on Prescription of Controlled Substances via Telemedicine

A new rule posted on the Office of Management and Budget (OMB) registry suggests that the Drug Enforcement Administration (DEA) is planning an additional extension of COVID-19 flexibilities for telemedicine prescribing of controlled substances, beyond the current expiration date of December 31, 2024. A new rule posted on the Office of Management and Budget (OMB) registry suggests that...
GLP-1 antagonist medication may reduce risk of overdose
Addiction Medicine Updates Articles of Interest

GLP-1 Agonists May Help Reduce Risk of Overdose and Alcohol Intoxication

A new study suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss, may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders. “It helps to underline another significant benefit of this class of medication,” Dr. Angela Fitch, the co-founder, and chief medical officer of...
CENTERS FOR MEDICARE MEDICAID (CMS) PUBLISHES FINAL RULES OUTLINING PAYMENT POLICIES FOR CALENDAR YEAR 2025
Articles of Interest Legislation

Medicare Finalizes New Payment Policies for 2025

On November 1, 2024, the Centers for Medicare and Medicaid Services (CMS) published final rules outlining payment policies for the calendar year (CY) 2025 payment year. The 2025 finalized MPFS proposes certain policy changes and some newly covered services that will enhance the care continuum. ASAM has provided a summary of these finalized changes below as well as at this link where...
Articles of Interest

What’s Working (or Not) in State Policies for Substance Use During Pregnancy

Substance use during pregnancy (or “prenatal substance use”) is becoming more common. Overdose and substance-related suicide are the leading preventable causes of maternal mortality, and prenatal substance use can increase the risk of miscarriage, birth defects, developmental disabilities, preterm birth, low birth weight, and decreased school readiness. State policy approaches to...
First-of-its-kind implant detects and treats opioid overdoses
Articles of Interest

First-of-its-kind implant detects and treats opioid overdoses

Since 1999, the opioid epidemic has killed around 645,000 people in America—a number that would no doubt be even higher were it not for naloxone, an opioid antagonist that can effectively reverse the effects of an overdose. However, time is critical: if naloxone is not administered promptly, the victim’s chances of survival diminish rapidly. In a paper published August 14 in Device, a...